GlassScriptPhysician profile
Kristen Coles Johnson
NPI 1396239224
$3,721.69
in general payments reported to CMS, 2019-2025
20 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $48.27 · 2023: $1,648 · 2024: $1,277 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.09 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,270.52 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $413.14 | 2021-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $407.34 | 2023-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $340.00 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $261.31 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $162.65 | 2021-2025 | Fanapt |
| Lundbeck LLC | $150.80 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $131.37 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $103.41 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $76.78 | 2022-2023 | Auvelity |
| Indivior INC. | $67.48 | 2023-2024 | Sublocade |
| Alkermes, INC. | $65.72 | 2021-2025 | Lybalvi |
| Genzyme Corporation | $55.63 | 2024 | |
| Neuronetics, INC. | $46.73 | 2023 | Neurostar Tms Therapy System |
| Avanir Pharmaceuticals, INC. | $40.78 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $33.84 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.48 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $24.69 | 2024 | |
| Tris Pharma INC | $20.90 | 2023 | Dyanavel Xr |
| Ars Pharmaceuticals Operations, INC. | $19.12 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.